Stemline Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences

NEW YORK, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that it will present at the Citi 2014 Global Healthcare and RBC Capital Markets Global Healthcare conferences in February.

Ivan Bergstein, M.D., Stemline's CEO, will host investor meetings at the Citi 2014 Global Healthcare Conference on Monday, February 24, 2014. The conference will be held at the Hilton New York Hotel in New York City.

Dr. Bergstein will also present at the RBC Capital Markets Global Healthcare Conference on Wednesday, February 26, 2014 at 4:05 PM ET. The conference will be held at the New York Palace Hotel in New York City. A live webcast of the presentation can be viewed on the Stemline website at www.stemline.com.

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline's clinical candidates, SL-401 and SL-701, have demonstrated clinical activity, including durable complete responses (CRs), in Phase 1/2 studies of patients with advanced hematologic and brain cancer, respectively. SL-401 is being advanced into later stage programs in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other rare malignancies, as well as additional hematologic cancers including acute myeloid leukemia (AML) and myeloma. SL-701 is being advanced into later stage trials of adults with second-line glioblastoma multiforme (GBM) and children with brainstem and non-brainstem glioma. For more information about Stemline Therapeutics, visit www.stemline.com.

Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACT: Mark Jacobson Director, Corporate Development Stemline Therapeutics, Inc. 750 Lexington Avenue Eleventh Floor New York, NY 10022 Tel: 646-502-2307 Email: mjacobson@stemline.comSource:Stemline Therapeutics, Inc.